Compare Medpace Holdings Inc (MEDP) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Meta Platforms Inc — how do they compare? Medpace Holdings Inc trades at $530.32 (market cap $15.08B), while Meta Platforms Inc trades at $647.49 (market cap $1.64T). The key difference: Meta Platforms Inc is far larger — about 108.8× Medpace Holdings Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | META | |
|---|---|---|
Market Cap | $15.08B | $1.64T |
Sector | Technology | Media |
52-Week High | $620.59 | $790.00 |
52-Week Low | $308.88 | $525.72 |
Enterprise Value | $14.55B | $1.65T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Meta Platforms (META) trades at $646.96, up 0.15% with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with $201B revenue in 2025, 32.84% net margin, and consistent earnings beats. Recent AI developments including Muse Spark launch and a $21B CoreWeave deal highlight growth initiatives. Technical indicators show support at $631 and resistance at $657, with RSI in neutral territory suggesting balanced momentum.
Outlook remains positive with 79% analyst buy ratings and $817 consensus target offering 26% upside. Key opportunities include AI monetization and revenue growth to $215B in 2026. Risks involve ongoing youth addiction lawsuits, regulatory scrutiny, and high capital expenditures. Institutional ownership trends show continued confidence with recent stake increases by American National Bank.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
